A Phase I, single-dose, randomized, double-blind, double-dummy, crossover study investigating abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users

Trial Profile

A Phase I, single-dose, randomized, double-blind, double-dummy, crossover study investigating abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary) ; Alprazolam
  • Indications Partial epilepsies
  • Focus Pharmacodynamics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top